Oscient's Factive tablets subject of presentations at European conference

By Elaine Rigoli

Tampa, Fla., April 4 - Oscient Pharmaceuticals Corp. said its lead product, Factive (gemifloxacin mesylate) tablets, is the subject of two poster presentations at the 16th European Congress of Clinical Microbiology and Infectious Diseases.

One presentation, "Clinical Outcome of Community-Acquired Pneumonia Infections Treated with Gemifloxacin: The Effect of Patient Risk Factors," addresses the efficacy of Factive when used for treating community-acquired pneumonia in patients with other risk factors, including prior antibiotic use, diabetes, chronic obstructive pulmonary disease and heart disease.

A meta-analysis of six previously completed phase 3 trials indicated a trend toward higher clinical success rates with gemifloxacin versus comparators in patients with these risk factors, according to a news release.

"As the incidence and prevalence of antibiotic-resistant pathogens increases in many European communities, patients suffering from serious respiratory tract infections in Europe may benefit from the availability of a new, potent agent, such as gemifloxacin," said Steven M. Rauscher, president and chief executive officer, in the release.

The second presentation, titled "Dual Action of Gemifloxacin in Acute Bacterial Sinusitis in Patients with Allergic Rhinitis: Antibacterial and Immunomodulatory Effects," examines the activity of Factive when treating acute bacterial sinusitis in patients with allergic rhinitis through a retrospective analysis of four pooled phase 3 studies.

Factive is approved for the treatment of mild to moderate community-acquired pneumonia and acute bacterial exacerbations of chronic bronchitis, but it is not approved for the treatment of acute bacterial sinusitis.

Oscient Pharmaceuticals is a biopharmaceutical company located in Waltham, Mass.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.